Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Table 4

Gender differences in adverse event reactions.

SOC/PT	Reports	ROR (95% CI)
Anemia	256	1.18 (1.03, 1.35)
Rash	173	0.88 (0.76, 1.01)
Depression	149	1.04 (0.87, 1.24)
Pruritus	113	0.80 (0.65, 0.97)
Vomiting	107	2.75 (2.21, 3.42)
Neutropenia	87	1.97 (1.54, 2.50)
Diarrhea	85	1.99 (1.57, 2.53)
Insomnia	81	1.40 (1.10, 1.76)
Platelet count decreased	80	0.91 (0.72, 1.15)
White blood cell count decreased	79	0.83 (0.65, 1.05)